series-a
Stage
2016
Founded
2
Investors
About
SciRhom is a German biotechnology company developing first-in-class therapeutic antibodies that target iRhom2 to treat major autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. Their lead candidate, SR-878, aims to block multiple pro-inflammatory signaling pathways.
Explore SciRhom's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.